Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
73
Views
1
CrossRef citations to date
0
Altmetric
Original Research

A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity

James A Chiarotto1 Department of Medicine, The Scarborough Health Network, Toronto, Ontario, CanadaCorrespondence[email protected]
&
George Dranitsaris2 Augmentium Pharma Consulting, Inc., Toronto, Ontario, Canada
Pages 4087-4094 | Published online: 19 May 2021

References

  • André T , Boni C , Navarro M , et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol . 2009;27:3109–3116. doi:10.1200/JCO.2008.20.6771 19451431
  • Kogan LG , Davis SL , Brooks GA . Treatment delays during FOLFOX chemotherapy in patients with colorectal cancer: a multicenter retrospective analysis. J Gastrointest Oncol . 2019;10(5):841–846. doi:10.21037/jgo.2019.07.03 31602321
  • Denduluri N , Patt DA , Wang Y , et al. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in oncology practices. J Natl Compr Canc Netw . 2015;13:1383–1393. doi:10.6004/jnccn.2015.0166 26553767
  • Chiarotto JA , Dranitsaris G . FOLFOX chemotherapy can safely be given to neutropenic patients with early-stage colorectal cancer for higher dose intensity and fewer visits. Support Care Cancer . 2016;24:2533–2539. doi:10.1007/s00520-015-3059-0 26694717
  • Chiarotto JA , Dranitsaris G . Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia. Support Cancer Care . 2013;21:2727–2731. doi:10.1007/s00520-013-1851-2
  • Debled M , Houédé N , Madranges N , et al. Does chemotherapy-induced neutropenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis. BJC . 2007;97:1642–1647. doi:10.1038/sj.bjc.6604094 18000502
  • Gotfrit J , Marginean H , Maroun JA , et al. Chemotherapy-induced neutropenia with FOLFOX in the adjuvant treatment of colorectal cancer. J Clin Oncol . 2020;38(4_supp):38. doi:10.1200/JCO.2020.38.4_suppl.38
  • Balducci L , Mo M , Abella E , et al. Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim. Am J Clin Oncol . 2014;37:603–610. doi:10.1097/COC.0000000000000141 25350463
  • Freifeld AG , Bow EJ , Sepkowitz KA , et al. Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Disease Society of America. Clin Infect Dis . 2010;52(4):e56–e93.
  • André T , Boni C , Mounedji-Boudiaf L , et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. NEJM . 2004;350:2343–2351. doi:10.1056/NEJMoa032709 15175436
  • Maroun JA , Marginean H . Hematologic toxicity with adjuvant FOLFOX in colon cancer. J Clin Oncol . 2016;34(15_suppl):e15062. doi:10.1200/JCO.2016.34.15_suppl.e15062
  • Smith TJ , Bohlke K , Lyman GH , et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology practice guideline update. J Clin Oncol . 2015;33:3199–3212. doi:10.1200/JCO.2015.62.3488 26169616
  • Aapro MS , Bohlius J , Cameron DA , et al. Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. EJC . 2010;2010(47):8–32.
  • Veitch Z , Khan OF , Tilley D , et al. Impact of cumulative chemotherapy dose on survival with adjuvant FEC-D chemotherapy for breast cancer. J Natl Compr Canc Netw . 2019;17(8):957–967. doi:10.6004/jnccn.2019.7286 31390594
  • Smoragiewicz M , Javaheri KR , Yin Y , et al. Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. J Gastrointest Cancer . 2014;45:460–465. doi:10.1007/s12029-014-9639-2 25012517
  • Grothey A , Sobrero A , Shields AF , et al. Duration of chemotherapy for stage III colon cancer. NEJM . 2018;378:1177–1188. doi:10.1056/NEJMoa1713709 29590544
  • Aspinall SL , Good CB , Zhao X , et al. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer . 2015;15:62–74. doi:10.1186/s12885-015-1038-y 25884851
  • Clemons MJ , Marshall E , Durig J , et al. A randomized phase-II study of BB-10010 (macrophage inflammatory protein-1?) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy. Blood . 1998;92:1532–1540. doi:10.1182/blood.V92.5.1532 9716580
  • Lalami Y , Klastersky J . Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol . 2017;120:163–167. doi:10.1016/j.critrevonc.2017.11.005 29198330

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.